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Abstract
Experimental autoimmune encephalomyelitis (EAE) is the most relevant animal model to study demyelinating diseases such
as multiple sclerosis. EAE can be induced by active (active EAE) or passive (at-EAE) transfer of activated T cells in several
species and strains of rodents. However, histological features of at-EAE model in C57BL/6 are poorly described. The aim of
this study was to characterize the neuroinflammatory and neurodegenerative responses of at-EAE in C57BL/6 mice by
histological techniques and compare them with that observed in the active EAE model. To develop the at-EAE, splenocytes
from active EAE female mice were harvested and cultured in presence of MOG35–55 and IL-12, and then injected
intraperitoneally in recipient female C57BL6/J mice. In both models, the development of EAE was similar except for starting
before the onset of symptoms and presenting a higher EAE cumulative score in the at-EAE model. Spinal cord histological
examination revealed an increased glial activation as well as more extensive demyelinating areas in the at-EAE than in the
active EAE model. Although inflammatory infiltrates composed by macrophages and T lymphocytes were found in the
spinal cord and brain of both models, B lymphocytes were significantly increased in the at-EAE model. The co-localization of
these B cells with IgG and their predominant distribution in areas of demyelination would suggest that IgG-secreting B cells
are involved in the neurodegenerative processes associated with at-EAE.
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Introduction
Experimental autoimmune encephalomyelitis (EAE) is a CD4+
T cell-mediated inflammatory demyelinating disease of the central
nervous system (CNS). Although no animal model recapitulates all
the underlying mechanisms of a complex human disease, the EAE
is the most commonly used experimental model for multiple
sclerosis (MS). There is a great heterogeneity in the susceptibility
and method of induction, also in the response to immunological or
neuropharmacological interventions [1–3]. This makes EAE a
very versatile system to use in translational neuroimmunophar-
macology, but the model needs to be tailored to the scientific
question being asked. EAE can be induced in many susceptible
species using several routes. Initially, animals were actively
immunized with self-antigen in the form of myelin components
or CNS homogenates emulsified in adjuvant [4–10]. Later on,
EAE was passively induced by adoptive transfer (at-EAE) of
encephalitogenic T cells with specificity to self–antigens [6,8,11–
13]. More recently, spontaneous EAE models have been also
developed using transgenic [14,15]. Active EAE is the easiest
inducible model giving fast results in screening the effects of drugs
on autoimmune inflammation. Years ago, Lewis rats were the
most popular animals used for EAE due mainly to their 100%
responsiveness after immunization with myelin basic protein
(MBP) [9]. Nowadays, C57BL/6 mice have become more popular
mainly for studies involving transgenic mice [14]. at-EAE is a very
useful model to answer questions related with the effector phase of
the disease. The encephalitogenic T cells can also be manipulated
in vitro to study the role of specific cytokines and other biological
agents before transfer to recipients. These cells can be labeled to
follow their localization, survival or interactions with other cell
types in the recipient. Moreover, the at-EAE model is of particular
interest to study the role of a variety of inflammatory molecules in
different aspects of disease development and regulation through
the use of gene-targeted donor or recipient animal strains [1,2].
Due to the lack of extensive histological studies in C57BL/6
comparing active and passive transfer EAE models when mice are
immunized with MOG35–55 is important to characterize by
histological techniques the neuroinflammatory and neurodegen-
erative responses taking into account the role not only of T cells
but also B cells which appear to have a more significative role in
the passive model.
Materials and Methods
Animals and EAE Model
C57BL/6J mice were purchased from Harlan Iberica (Spain)
and maintained under regulated light and temperature condi-
tions at the animal facilities of the Faculty of Pharmacy,
University of Barcelona. Animal experiments were done in
accordance with the Guidelines of the European Union Council
(86/609/EU) and Spanish Government (BOE 67/8509-12), and
approved by the Ethics and Scientific Committees from the
University of Barcelona and registered at the ‘‘Departament
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d’Agricultura, Ramaderia i Pesca de la Generalitat de Catalu-
nya’’. Sixty-eight female mice 6–8 weeks old were immunized
with an encephalitogenic cocktail containing MOG35–55 (150 mg/
mouse) and H37R Mycobacterium tuberculosis (1 mg/mouse) in
complete Freund’s adjuvant (CFA). Female mice were injected
intraperitoneally (i.p.) with pertussis toxin from Bordetella
pertussis (500 ng/mouse), 1 h and 48 hours after immunization.
Mice were weight each day after immunization and EAE
symptoms (mobility loss and hind limb paralysis) were evaluated
from day five after immunization in according with this score
scale: 0 = no symptoms; 1= total loss of tail tonicity; 2 = difficulty
in righting; 3 = unsteady gait and mild paralysis; 4 = total hind-
limb paralysis and incontinence; 5 = total paralysis; 6 =moribund
or death. During EAE score evaluation none animal was
sacrificed, since the score did not reach 5. Mice with a score
of 4 had hind leg paralysis and incontinence on day 17 after
immunization. However, on the day of sacrifice (day 19)
improvement was observed in mice and the mean score was
less than 3.5. Wet food and easier access to fresh water was
supplied when the animals had paralysis of one or two of the
hind legs. Moreover, if a mouse had less than 16 grams of
weight, it was administered daily with 200 ml of saline
glycosylated solution. On day 19 after immunization, mice were
sacrificed by an overdose of anesthesia (ketamine and xylazine,
100 and 20 mg/kg respectively).
Adoptive Transfer of Experimental Autoimmune
Encephalomyelitis (at-EAE Model)
To develop the at-EAE, spleens from active female EAE mice
(mean score = 2.860.2) were extracted 12 days after immuniza-
tion. Spleens were dissected and passed through a 100 mm filter
(FalconTM) to obtain a single cell suspension. Cells were incubated
with a red blood cells lysis buffer (Ammonium chloride NH4Cl
155 mM, potassium bicarbonate KHCO3 10 mM, EDTA pH 8.0
0,01 mM) for 59 at 4uC. After one centrifugation (500 rcf 59 4uC),
cells were cultured in presence of MOG35–55 (50 mg/ml) and IL-12
(25 ng/ml) in a concentration of 5?106 cells/mL. After 72 hours,
20?106 splenocytes/mouse were injected i.p. in 33 recipient female
C57BL/6J mice with 7 weeks old (18–20 g) to induce at-EAE. The
experiment was repeated 3 times. In parallel, six others female
C57BL/6J mice were immunized to develop an active EAE used
as positive control, and 3 CFA and 3 untreated mice as negative
control. On day 19 after cells injection, animals were anesthetized
and perfused with 4% of PFA (paraformaldehyde). The brains and
lumbar spinal cord were carefully removed, post-fixed in PFA for
48 h, paraffin processed, cut in 5 mm sections and neurohistolog-
ical techniques were performed. Three mice were sacrificed on
day 46 after treatment to evaluate the long-term evolution of at-
EAE symptoms.
Histology
Four sequential sections from each case, controls and immu-
nized mice, were deparaffinised, hydrated, and washed in PBS and
then stained for each histological procedure. For hematoxylin and
eosin staining, we used the standard protocol for Harris
hematoxylin. For luxol fast blue technique, slides were stained
with luxol fast blue solution at 56uC overnight, washed with 95%
ethanol and distilled water. After that, slides were differentiated in
lithium carbonate solution (0.05%) and 70% ethanol for 30
seconds in each solution. After several washes in distilled water,
slides were ethanol dehydrated and coverslipped with DPX and
analyzed under bright light microscope. Alternatively, some
sections were counterstained with cresyl violet solution. For the
FluoroJade histofluorescent staining we used the protocol from
Figure 1. EAE induction in C57/BL6 mice by adoptive transfer
of encephalitogenic cells (at-EAE) or active immunization
(active EAE). Incidence in at-EAE mice (A) and active EAE mice (B)
between day 7 and 15 after immunization or adoptive transfer. (A) at-
EAE symptoms appeared on day 8 after immunization and the 100% of
incidence is reached on day 14. (B) Active EAE symptoms appeared on
day 10 after cells injection and the 100% of incidence is reached on day
15. (C) Average score of at-EAE and active EAE from the day of
immunization or adoptive transfer to day 19. Increasing the score in at-
EAE mice and active EAE is significant with respect to control mice (at-
EAE: day 11, *, p,0.05; day 12, *, p,0.05; day 13, **, p,0.01; day 14, ***,
p,0.001; day 15, **, p,0.01; day 17, **, p,0.01; day 18, **, p,0.01; 19,
*, p,0.05; active EAE: day 18, *, p,0.05; day 19, *, p,0.05). After
immunization or adoptive transfer score is significantly higher in at-EAE
than in active EAE (day 10,##, p,0.01; day 11,###, p,0.001; day 12,
###, p,0.001; day 13 ##, p,0.01; day 14, ##, p,0.01). (D) Weight
variations during EAE development. Weight loss in at-EAE mice is
significant with respect to control mice between days 14 and 19 (day
14, **, p,0.01; day 17, **, p,0.01; day 18, **, p,0.01; and day 19, **,
at-EAE Characterization in C57BL/6 Mice
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Millipore. Briefly, the slides were washed in distilled water and
incubated in a 0.06% potassium permanganate solution for
15 min. After that, they were incubated in a 0.001% FluoroJade
staining solution for 30 min. Following the fluorescent staining, the
slides were washed in distilled water and dried at 50uC. Then they
were immersed in xylene and coverslipped with DPX, and
microscopically analyzed under fluorescent/FITC filter.
Immunohistochemistry
Sections were deparaffinised, hydrated, and washed in PBS
containing 0.1% triton (PBS-T). Antigen retrieval was performed
incubated the sections in citrate buffer (pH=6.0) at 95uC during
30 minutes. Then, sections were rinsed in citrate buffer and PBS at
room temperature. After that, the sections were treated with 2%
H2O2 in methanol during 10 minutes, rinsed in PBS-T, blocked
with 10% of fetal bovine serum and incubated overnight with one
of the following primary antibodies: anti-GFAP (1:300, Dako),
anti-CD3 (1:100, Abcam), anti-CD-45R (1:100, BD Pharrmingen),
anti-CD-138 (1:100, Abcam), anti-MBP (1:300, Millipore), anti-
MOSP (1:500, Millipore), anti-NeuN (1:100, Sigma-Aldrich), anti-
MAP2 (1:500, Sigma-Aldrich), anti-caspase-3-cleaved (1:100,
Millipore), anti-IgG (1:100, Thermo Scientific). Sections were
then incubated with biotinylated goat anti-rabbit or mouse
antibody (1:500, Sigma) and then with ExtrAvidin-HRP (1:500,
Sigma-Aldrich). For microglia and macrophages staining we used
biotinylated tomato isolectin (1:200, Sigma-Aldrich) and then the
sections were incubated with ExtrAvidin-HRP (1:500, Sigma-
Aldrich). Finally, the sections were developed with 0.05%
diaminobenzidine-0.01% H2O2 (brown colour stain), washed in
PBS-T and mounted in DPX medium. Alternatively, some
sections were counterstained with methyl green.
Immunopositive Cell Counting and Semiquantitative
Histological Analysis
Two observers, blinded to the experimental methodology,
analyzed all sections in a light microscope Eclipse 901 (Nikon) and
images were captured with a digital camera (Nikon). All
immunopositive cells in the gray or white matter of lumbar spinal
cord were counted in four randomly chosen sections for each
mouse of each group: control (n = 4), active EAE (n= 7), and at-
EAE (n = 10). Semiquantitative histological evaluation for glial
markers (GFAP, isolectin and Iba-1; 406 magnified microscope
field), cell infiltration markers (CD-45R and CD3; 406magnified
microscope field), demyelination markers (MOSP and MBP; 106
magnified microscope field), neuronal markers (NeuN and MAP-
2; 106magnified microscope field) and neurodegeneration marker
(FluoroJade; 206magnified microscope field) was conducted and
scored blindly using the following scale: 0 = absent of label or no
positive cells, 1 = very weak label or less than 5 positive-cells/
microscope field, 2 =weak label or 5 to 10 positive cells/
microscope field, 3 =moderate label or 10 to 15 positive cells/
microscope field, 4 = strong label or 15 to 20 positive cells/
microscope field, 5 = very strong label or more than 20 positive
cells /microscope field. For NeuN and CD-45R, the histological
score increased to 6 due to high cell density was more than 50 cells
per microscope field.
Double Immunofluorescence
For double immunohistofluorescence, the sections were depar-
affinised, hydrated, washed in PBS and incubated in citrate buffer
(pH=6.0) at 95uC during 30 minutes. After, several washes in
PBS, the sections were blocked with 10% of FBS and incubated
overnight at 4uC with two of following primary antibodies: anti-
CD3 (1:100, Abcam), anti-CD-45R (1:100, BD Pharrmingen),
anti-CD-138 (1:100, Abcam) or anti-IgG (1:500, Vector). After
rinsing in PBS-T, sections were incubated 1 hour at room
temperature with goat anti-rabbit ALEXA 546 (1:500) and/or
goat anti-rat and/or anti-mouse ALEXA 488 (1:500) secondary
antibodies and DAPI. For IgG immunolabelling, the sections were
incubated first with goat anti-mouse biotinylated and then with
ExtrAvidin-ALEXA 488 or 546. Finally, after washed in PBS-T
the sections were mounted in mowiol medium.
Data Presentation and Statistical Analysis
Histological techniques were repeated at least 3 times for each
independent experiment (n = 3). All statistical analyses were
performed using Kruskal-Wallis nonparametric test followed by
Dunn’s post analysis. The data were presented as mean values 6
SEM. Values of p,0.05 were considered statistically significant.
All statistical analyses were performed by GraphPad Prism
software (GraphPad Software, Inc., La Jolla, USA).
Results
Clinical Development of the at-EAE
Mice injected with MOG35–55 activated T cells developed the
first neurological symptoms at day 8 reaching 100% of incidence
on day 14 (Figure 1A, C), while in the active EAE neurological
symptoms starting two days later and reaching 100% of incidence
on day 15 (Figure 1B, C). At 100% of incidence, all the animals
showed progressive weight loss, limp tail, and mild-to-moderate
paraparesis. The loss of weight in the at-EAE animals occurred at
the same time of the first clinical symptoms, while in the active
p,0.01). Significant weight differences are observed between at-EAE
and active EAE on day 2 (###, p,0.001), day 7 (#, p,0.05) and day 12
(#, p,0.05). Data are representative of three separate experiments.
Each group represents the mean of 6 mice for control, 13 mice for both
at-EAE and active EAE, with SEM error bars. All statistical analyses were
performed using Kruskal-Wallis nonparametric test followed by Dunn’s
post analysis. Values of p , 0.05 were considered statistically
significant.
doi:10.1371/journal.pone.0052361.g001
Table 1. at-EAE versus active EAE models.





atEAE 13 EAE day 14 (100 %) 10.4 6 0.4 3.3 6 0.1 4.1 6 0.1 28.2 6 1.7
Active EAE 13 EAE day 15 (100 %) 13.0 6 0.4 2.8 6 0.2 3.7 6 0.2 16.4 6 1.3
*** ** NS ***
**, p,0.01; ***, p,0.001; NS, not statistically significant; Kruskal-Wallis test (Dunn’s post analysis).
doi:10.1371/journal.pone.0052361.t001
at-EAE Characterization in C57BL/6 Mice
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Figure 2. Glial activation in lumbar spinal cord. Astroglial GFAP immunostaining is observed in lumbar spinal cord of at-EAE mice (B) and active
EAE mice (C) when compared with control (A). Isolectin labeling in the lumbar spinal cord show increase in at-EAE mice (E) compared with active EAE
(F) and control mice (D). Iba-1 immunostaing (microglial marker) is up-expressed in the lumbar spinal cord of at-EAE mice (H) compared with active
EAE (I) and control mice (G). Semiquantitative histological analysis of glial markers in lumbar spinal cord (J) and in ventricular regions of brain (K). A
significant increase of glial-positive cells is observed in at-EAE versus control both in lumbar spinal cord (GFAP: *, p,0.05; Isolectin and Iba-1: **,
p,0.01) and brain (GFAP and Isolectin: *, p,0.05). The increased of Isolectin-positive cells is significantly higher in at-EAE than in active EAE (#,
p,0.05). Data are representative of three separate experiments. Each group represents the mean of 4 mice for control, 10 mice for at-EAE and 7 mice
for active EAE, with SEM error bars. All statistical analyses were performed using Kruskal-Wallis nonparametric test followed by Dunn’s post analysis.
Values of p , 0.05 were considered statistically significant. Magnification bar 150 mm.
doi:10.1371/journal.pone.0052361.g002
at-EAE Characterization in C57BL/6 Mice
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EAE the weight loss follows two days after the appearance of the
symptoms (Figure 1C, D).
The mean maximum score reached during the time course of
the experiment was 4.0860.08 in at-EAE animals and 3.6960.18
in active EAE (Table 1). However, this difference in the mean
maximum score was not statistically significant. By contrast, the
mean scores at the end of the experiment were significantly higher
(p,0.01) in at-EAE than in active EAE (3.2960.11 and
2.7560.15, respectively, Table 1). Therefore, the cumulative
EAE score was significantly higher (p,0.001) in at-EAE than in
active EAE (28.1961.69 and 16.3861.34, respectively, Table 1).
Glial Activation
Histological examination of the CNS tissue from the at-EAE
showed an increase in the immunolabeling of glial markers, both
for astrocytes and microglia/macrophages in comparison with
control animals (Figure 2). GFAP staining showed hypertrophic
astrocytes in spinal cord of at-EAE and active EAE animals. No
significant differences in GFAP staining were found between at-
EAE and active EAE (Figure 2A–C, J). Moreover, the presence of
microglia/macrophages with amoeboid morphology stained by
isolectin (Figure 2D–F) and Iba-1 (Figure 2G–I) evidenced an
undergoing inflammatory process in both models. However,
isolectin staining was significantly increased in at-EAE compared
with the active model (Figure 2 D–J), although the glial activation
was more discrete in the brain that in the spinal cord (Figure 2K).
Demyelination and Neuronal Damage
Luxol fast blue staining showed demyelinated areas in the
lumbar spinal cord of at-EAE and active EAE mice (Figure 3A–C).
Immunostaining for MOSP (Figure 3D–F) and MBP (Figure 3G–
I), markers for oligodendrocytes and myelin respectively, showed a
decrease in the intensity of the markers in both at-EAE and active
EAE models in comparison with controls. Furthermore, MOSP
quantification was significantly lower in the at-EAE in comparison
with the active model or control mice indicating more extreme
demyelination in the spinal cord of at-EAE (Figure 3P). In
contrast, we did not observe demyelination in the brain (data not
shown). In order to evaluate neuronal damage, we performed
NeuN staining in the spinal cord of the animals. We found no
neuronal loss in at-EAE mice although an up-regulation of NeuN
protein was observed (Figure 3J–L). Then we performed caspase-
3-cleaved immunohistochemistry and we did not detect apoptotic
cells confirming the previous result (data not shown).
FluoroJade stain was also used in order to label degenerating
neurons (Figure 3M–O). In the at-EAE model neuronal loss was
not detectable by NeuN staining but when FluoroJade was used a
large number of neurons was stained indicating that, even though
neurons were not dead, they had begun a degenerative process
(Figure 3Q). In the active EAE model a significant lower number
of positive cells was observed in comparison with the at-EAE
model (Figure 3N–O).
Cell Infiltration in the CNS
In the lumbar spinal cord of at-EAE mice and active EAE, H/E
staining showed inflammatory infiltrates mainly localized around
the central canal and marginal zone (overlapping the demyelin-
ation areas) (Figure 4A–C). The localization and size of the
infiltrates was similar in both models. However, the number of
infiltrates was higher in at-EAE. To study the composition of the
inflammatory infiltrates we immunostained for different cell
markers. As shown previously (Figure 2), some macrophages from
the periphery were present in the inflammatory infiltrates. CD3 (T
lymphocytes) and CD-45R (B lymphocytes) positive cells were also
present in the inflammatory infiltrates (Figure 4D–F and G–I,
respectively). Semiquantitative histological analysis showed that in
both EAE models the number of T cells (CD3 positive cells) in the
infiltrates was similar but B cells (CD-45R positive cells) were
significantly increased in the at-EAE in comparison with the active
EAE model, mainly in demyelination areas (Figure 4J). Similar
results were obtained in the brain of at-EAE mice; however, the
total number of inflammatory infiltrates was lower than in the
spinal cord (Figure 4J–K).
Involvement of B Cells in the Pathogeneses of the at-EAE
Model
Although CD-45R is widely used as a marker for B cells, it has
been reported that CD-45R can also be found in some subsets of
activated T cells [16,17]. For this reason, we studied whether these
CD-45R-positive cells found in at-EAE were antibodies producing
cells by immunocolocalization with mouse IgG. The results
obtained showed that most of the CD-45R-positive cells co-
localized with IgG (Figure 5A–D), and only a few cells co-localized
with CD3 (Figure 5F–I), suggesting that most of them were IgG
secreting cells. In addition, we used syndecan 1 (CD-138), another
B cell marker which selectively stains plasma cells (antibodies
producing cells), and we found that many of the CD-138-positive
cells co-localized with mouse IgG (Figure 5K–N) but not with CD-
45R-positive cells (Figure 5P–S), suggesting the existence of two
distinct B cell subpopulations. In control mice, there were no cells
stained by these markers (Figure 5 E, J, O, T).
Discussion
In the current study we developed and characterized by
histological techniques an at-EAE model in C57BL/6 mice using
the MOG35-55 peptide and IL-12. This at-EAE was a very
reproducible model with high incidence, in contrast with Cravens
and colleagues conclusions arguing that this mouse strain is
relatively resistant to this method of EAE induction [18]. The
disease presented as a typical EAE, similar to that described after
injection with MBP or PLP [19]. The development of EAE was
similar in both transfer and active models except for the earlier
onset of symptoms and the higher EAE cumulative score in the at-
EAE. However, the most striking differences were the increased
Figure 3. Demyelination and neurodegeneration markers in the lumbar spinal cord. The demyelination is clearly demonstrated by a loss
of signal in the luxol fast blue staining (A–C) and MOSP (D–F) and MBP (G–I) immunostaining of at-EAE (B, E and H, respectively) and active EAE mice
(C, F and I, respectively) when compared with control mice (A, D and G, respectively). NeuN immunostaining in control (J), at-EAE mice (K) and active
EAE (L). None FluoroJade staining is observed in control mice (M), while some FluoroJade positive cells are observed in at-EAE mice (N) and few
positive cells are observed in active EAE mice (O). Semiquantitative histological analysis of demyelination (P) and neurodegeneration (Q) markers in
lumbar spinal cord. A significant decrease of immunostaining is observed in at-EAE versus control in lumbar spinal cord (MOSP and MBP: *, p,0.05).
The decrease of MOSP immunostaining in at-EAE mice is significant with respect to the active EAE mice (#, p,0.05). No changes are detected in the
NeuN-positive cell number meanwhile an increase in the number of degenerating neurons (FluoroJade) is observed in at-EAE mice with respect to
control mice (**, p,0.01). Data are representative of three separate experiments. Each group represents the mean of 4 mice for control, 10 mice for
at-EAE and 7 mice for active EAE, with SEM error bars. All statistical analyses were performed using Kruskal-Wallis nonparametric test followed by
Dunn’s post analysis. Values of p,0.05 were considered statistically significant. Magnification bar 200 mm.
doi:10.1371/journal.pone.0052361.g003
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Figure 4. Lymphocyte infiltrates in lumbar spinal cord. H/E technique show absence of blood infiltrates in control mice (A) while many
infiltrates are observed in at-EAE (B) and active EAE mice (C). No T cells (CD3 marker) immunostaining is observed in lumbar spinal cord of control
mice (D). Many T cells are detected in the parenchyma of at-EAE mice and active EAE (E and F, respectively). No B-cells (CD-45R marker)
immunostaining is observed in lumbar spinal cord of control mice (G). Many B cells are observed mainly in at-EAE mice (H) while few B-cells are
detected in active EAE (I). Semiquantitative histological analysis of infiltration markers in lumbar spinal cord (J) and brain (K). A significant increase of
CD-45R-positive cells is detected in at-EAE mice with respect to control mice both in lumbar spinal cord (**, p,0.01) and brain (**, p,0.01). The
increase of CD-45R-positive cells was higher in at-EAE than in active EAE , both in lumbar spinal cord (#, p,0.05) and in brain (##, p,0.01). An
increase in the number of CD3-positive cells has been observed in at-EAE in both CNS areas (**, p,0.01). Data are representative of three separate
at-EAE Characterization in C57BL/6 Mice
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glial activation as well as more extensive areas of demyelination
and neurodegenerative changes in the lumbar spinal cord of at-
EAE. In addition, although the inflammatory infiltrates composed
by macrophages and T lymphocytes were similar in both models,
B lymphocytes were significantly increased in the at-EAE model.
The co-localization of these B cells with IgG is a finding not
reported previously and suggests the presence of antibody-
secreting cells. Moreover, these IgGs-secreting B cells were
restricted to degenerating areas in which we demonstrated to
have a glial activation (GFAP, Isolectin and Iba-1 immunostain-
ing), demyelination (MOSP and MBP immunostaining) and a
neurodegeneration (FluoroJade staininig).
In fact, these findings are not unexpected. Although the classic
early work regarding EAE studies established that CD4+ T cells
were the critical effectors driven the disease, soon it became clear
that B cells and their antibody products have essential roles too.
Willenborg and Prowse demonstrated that rats with B lymphocyte
depletion by administration of anti-IgM failed to develop MBP
mediated EAE [20] Moreover, these anti-IgM treated rats,
resistant to EAE, develop EAE symptoms when treated with
anti-MBP serum [21]. Weber and colleagues induced murine EAE
by recombinant MOG (rMOG), a model in which B cells are
considered to contribute pathogenically, or MOG35–55 peptide,
which does not require B cells. In the model induced by rMOG, B
cells became activated and as antigen presenting cells (APCs),
promoted differentiation of proinflammatory MOG-specific Th1
and Th17 cells. B-cell depletion with anti CD-20 treatment
prevented or reversed the EAE, which was associated with less
CNS inflammation, elimination of meningeal B cells, and
reduction of MOG-specific Th1 and Th17 cells. All these findings
together suggested distinct roles for B cells in CNS autoimmunity
and the importance of the differences in immune responses to
MOG protein and peptide when choosing an EAE model for
testing novel B cell-targeting agents for MS [22].
The at-EAE model presented here could be a useful tool for
studying the role of B lymphocytes in the pathogenic mechanisms
of the MS and for testing potential new therapies focused in B cells
and humoral immunity. Other adoptive transfer models that use
MBP as encephalitogenic peptide concluded that the disease was
not dependent upon the presence of B cells and antibody
production [21], without taking into account that the pathogenic
role of antibodies in EAE studies depends on the specificity of the
antibodies. MBP has an intracellular localization while MOG cell
surface expression makes it accessible to antibody recognition,
reason why MOG could be necessary in order to have B cells and
antibody production in our at-EAE model. Other MBP EAE
passive models in rats used MOG antibody injections in order to
study the role of autoantibodies in the pathogenesis of MS [23,24],
experiments. Each group represents the mean of 4 mice for control, 10 mice for at-EAE and 7 mice for active EAE, with SEM error bars. All statistical
analyses were performed using Kruskal-Wallis nonparametric test followed by Dunn’s post analysis. Values of p , 0.05 were considered statistically
significant. Magnification bar 150 mm.
doi:10.1371/journal.pone.0052361.g004
Figure 5. Double immunostaining for B cells in at-EAE and control spinal cord sections. DAPI (A), CD-45R (B), IgG (C), merge (D) at-EAE
fluorostaining sections, and control merge (E) fluorostaining sections. DAPI (F), CD3 (G), CD-45R (H), merge (I) at-EAE fluorostaining sections, and
control merge (J) fluorostaining sections. DAPI (K), CD-138 (L), IgG (M), merge (N) at-EAE fluorostaining sections, and control merge (O) fluorostaining
sections. DAPI (P), CD-138 (Q), CD-45R (R), merge (S) at-EAE fluorostaining sections, and control merge (T) fluorostaining sections. Magnification bar
150 mm.
doi:10.1371/journal.pone.0052361.g005
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but in these models the antibody is injected and there are few B
cells present in the CNS making difficult the study of any direct
role of B cells in the pathogenesis that is not mediated by
antibodies. Is crucial taking into account that, apart from secreting
demyelinating antibodies, B cells present myelin autoantigen by
concentrating local autoantigen with their immunoglobulin
receptors [15,25]. B cells also contribute to create a particular
cytokine environment, being able to produce interleukin 10 (IL-10)
[26,27]. IL-10 is a pleiotropic cytokine that exhibits potent anti-
inflammatory activity [28]. The mechanism implicated, location
and cellular targets of B cell-derived IL-10 regulation in EAE are
not known because low numbers of B cells enter the CNS during
disease. The high amounts of B cells found in the inflammatory
infiltrates in this model make it useful to study the role of B cells in
the pathogenesis of the disease.
Moreover, the model described in the paper allows the study of
all the pathogenic mechanisms related with the antibody
production by B cells but also other possible neurodegenerative
mechanisms not antibody-related as for example T:B cell
interactions. In this sense, as the model is developed under a
C57BL/6 background, transgenic variants are possible in order to
answer specific questions.
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